Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in human immunodeficiency virus-associated, B-cell non-Hodgkin lymphoma

Four cycles of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy is as effective as six cycles in low-risk diffuse large B-cell lymphoma (DLBCL). Here we report a post-hoc analysis of a prospective clinical trial in patients with human immunodeficiency vir...

Descripción completa

Detalles Bibliográficos
Autores principales: Sparano, Joseph A., Lee, Jeannette Y., Kaplan, Lawrence D., Ramos, Juan Carlos, Ambinder, Richard F., Wachsman, William, Aboulafia, David, Noy, Ariela, Henry, David H., Ratner, Lee, Cesarman, Ethel, Chadburn, Amy, Mitsuyasu, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927888/
https://www.ncbi.nlm.nih.gov/pubmed/32107337
http://dx.doi.org/10.3324/haematol.2019.243386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927888/
https://www.ncbi.nlm.nih.gov/pubmed/32107337
http://dx.doi.org/10.3324/haematol.2019.243386

Ejemplares similares